April 06, 2019
Circassia’s Duaklir Approved by FDA for Maintenance Treatment of COPD
Circassia announced that the U.S. Food and Drug Administration (FDA) approved its medication Duaklir for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The company plans to launch the therapy in the United States in the second half of 2019. Duaklir is a combination of two long-acting bronchodilators: aclidinium bromide (400 mcg) and formoterol fumarate (12 mcg). It…
